Astellas Pharma is one of Japan's leading pharmaceutical companies, now developing a growing international profile. Its top-selling drug for the past few years has been the prostate cancer treatment Xtandi, sold in more than 70 countries, backed by supporting products Eligard and Gonax. Other key medicines include Vesicare for over-active bladder and its successor Myrbetriq/Betmiga, and transplantation drug Prograf. It also owns lung cancer drug Tarceva, which is co-promoted by Roche/Genentech in Europe and the US. In its domestic market it has local rights to several well-known drugs including Pfizer's Lipitor, and AstraZeneca's Seroquel and Symbicort, and agreed a Japanese joint venture in 2013 with US biotech giant Amgen. Astellas Pharma was created in 2005 from the merger of two existing Japanese drug companies, Yamanouchi Pharmaceutical (estbalished 1923) and Fujisawa Pharmaceutical (which traced its heritage back to 1894). Global revenues for year ending 2018 were approximately $11.7bn, including approx $2.7bn from Xtandi (up almost 17% year-on-year), $2.1bn from the over-active bladder franchise, and $1.8bn from Prograf. Pfizer is now Astellas' co-promotion partner for Xtandi in the US (following its acquisition of original partner and co-developer Medivation). Japan accounted for just under a third of group revenues, but sales from the Americas and EMEA have doubled in five years and now represent more than 60% of the total. Kenji Yasukawa is CEO. Adbrands does not currently profile this company but subscribers may access account assignments and contact information. The searchable account assignments database is available to full subscribers to Adbrands.net premium services. Click here to access Adbrands account assignments (subscribers only); or see here for information on how to subscribe.
Which agencies handle advertising for Astellas? Find out more from the Adbrands Account Assignments database
Who are the competitors of Astellas? See Pharmaceutical Sector for other companies
Capsule checked 20th November 2018
Adbrands Company Profiles assess more than 1,000 leading advertisers, brands and agencies, and examine each company's business record, geographic strength and comparative performance within its chosen sector, including strengths and weaknesses, history, up-to-date news and top-line financial information. What else does the company do? How did it originate? What other brands does it own? How is it performing in the market? With what other businesses is it affiliated?
Adbrands Account Assignments is a database tracking account management for the world's leading brands and companies. In other words, which advertising agency handles which accounts in which countries. Fully searchable by brand, brandowner company or advertising agency, the database now contains more than 35,000 worldwide account assignments for over 9,500 leading brands.
New to the industry? See here for a brief summary of how the agency business is structured.
All rights reserved © Mind Advertising Ltd 1998-2019